

Tai-Ling Chao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7092659/publications.pdf>

Version: 2024-02-01

8
papers

172
citations

1477746

6
h-index

1588620

8
g-index

8
all docs

8
docs citations

8
times ranked

148
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. <i>Pharmaceutics</i> , 2022, 14, 176.	2.0	6
2	Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain. <i>Antiviral Research</i> , 2022, 200, 105290.	1.9	3
3	Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4050.	1.8	17
4	Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. <i>Science Translational Medicine</i> , 2022, 14, eabm0899.	5.8	68
5	Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	27
6	Remdesivir and Cyclosporine Synergistically Inhibit the Human Coronaviruses OC43 and SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 2021, 12, 706901.	1.6	16
7	Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives. <i>Frontiers in Pharmacology</i> , 2020, 11, 606097.	1.6	17
8	Enhancement of the IFN- β -induced host signature informs repurposed drugs for COVID-19. <i>Heliyon</i> , 2020, 6, e05646.	1.4	18